Orthostatische Hypotonie und nächtliche Hypertonie bei Parkinson-Patienten

Zusammenfassung

Die orthostatische Hypotonie (OH) sowie eine Neigung zu Blutdruckerhöhung in der Nacht und im Liegen (supine hypertension) sind typische nicht motorische Symptome im Rahmen der autonomen Störung bei Parkinson-Patienten. Deren vernachlässigte klinische Bedeutung und Pathogenese – teilweise iatrogen bedingt – sowie pragmatische Therapieoptionen werden in dieser Übersicht behandelt.

Summary

The orthostatic hypotension (OH) as well as the tendency to develop a supine hypertension are typical non-motoric symptoms within the autonomic disorder in patients with Parkinson’s disease. Their clinical relevance, pathogenesis, distribution on various parkinson syndromes and the therapeutic options will be explained in following text.

Schlüsselwörter

Orthostatische Dysregulation - nächtlicher Bluthochdruck - Parkinson-Syndrome - idiopathisches Parkinson-Syndrom

Keywords

Orthostatic dysregulation - nocturnal hypertension - parkinsonism - Parkinson´s disease

• Literatur

• 1 Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276 (07) 374-9.
• 2 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55 (03) 181-4.
• 3 Mesec A, Sega S, Kiauta T. The influence of the type, duration, severity and levodopa treatment of Parkinson’s disease on cardiovascular autonomic responses. Clin Auton Res Off J Clin Auton Res Soc 1993; 03 (05) 339-44.
• 4 McKeigue PM, Reynard JM. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet 2000; 355 (9202): 486-8.
• 5 Agarwal R, Light RP, Bills JE, Hummel LA. Nocturia, nocturnal activity, and nondipping. Hypertension 2009; 54 (03) 646-51.
• 6 Pennestri MH, Montplaisir J, Colombo R, Lavigne G, Lanfranchi PA. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 2007; 68 (15) 1213-8.
• 7 Kenney WL, Chiu P. Influence of age on thirst and fluid intake. Med Sci Sports Exerc 2001; 33 (09) 1524-32.
• 8 Fereshtehnejad SM, Lökk J. Orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Park Dis 2014; 2014: 475854.
• 9 Braak H, Sastre M, Bohl JRE, de Vos RAI, Del Tredici K. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol (Berl) 2007; 113 (04) 421-9.
• 10 Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen ENHSteur, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24 (02) 197-211.
• 11 Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S. Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord Off J Mov Disord Soc 2009; 24 (15) 2299-301.
• 12 Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009; 73 (20) 1699-704.
• 13 Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009; 10 (03) 211-23.
• 14 Fuller PM, Saper CB, Lu J. The pontine REM switch: past and present. J Physiol 2007; 584 (Pt3): 735-41.
• 15 Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003; 42 (01) 33-84.
• 16 Carter ME. et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat Neuro sci 2010; 13 (12) 1526-33.
• 17 Thompson WO, Thompson PK, Dailey ME. The effect of posture upon the composition and volume of the blood in man. J Clin Invest 1928; 05 (04) 573-604.
• 18 Freeman R. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci Basic Clin 2011; 161 (1–2): 46-8.
• 19 Morgan TO, Anderson A. Different drug classes have variable effects on blood pressure depending on the time of day. Am J Hypertens 2003; 16 (01) 46-50.
• 20 Brandenberger G. et al. Twenty-four-hour profiles of plasma renin activity in relation to the sleepwake cycle. J Hypertens 1994; 12 (03) 277-83.
• 21 Senard JM, Chamontin B, Rascol A, Montastruc JL. Ambulatory blood pressure in patients with Parkinson’s disease without and with orthostatic hypotension. Clin Auton Res Off J Clin Auton Res Soc 1992; 02 (02) 99-104.
• 22 Sommer S, Aral-Becher B, Jost W. Nondipping in Parkinson’s disease. Park Dis 2011; 2011: 897586.
• 23 Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003; 42 (02) 136-42.
• 24 Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27 (01) 130-5.
• 25 Müller JFM, Tönnesmann U, Schaupp S, Franz IW. Nocturnal blood pressure and myocardial ischemia in patients with CAD. J Hypertens 1996; 14: 252.
• 26 Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res Off J Clin Auton Res Soc 2008; 18 Suppl (Suppl. 01) 2-7.
• 27 Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord Off J Mov Disord Soc 2008; 23 (06) 837-44.
• 28 Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RMA. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011; 17 (10) 724-9.
• 29 Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Parkinsonism Relat Disord 2011; 17 (08) 625-8.
• 30 Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012; 46 (03) 572-80.
• 31 Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2013; 260 (09) 2212-9.
• 32 Truong DD, Wolters EC. Recognition and management of Parkinson’s disease during the premotor (prodromal) phase. Expert Rev Neurother 2009; 09 (06) 847-57.
• 33 Wenning GK. et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67 (05) 620-3.
• 34 Streeten DH, Anderson GH. Delayed orthostatic intolerance. Arch Intern Med 1992; 152 (05) 1066-72.
• 35 Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK. Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory?. Mov Disord Off J Mov Disord Soc 2009; 24 (12) 1747-51.
• 36 Gibbons CH, Freeman R. Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance. Neurology 2006; 67 (01) 28-32.
• 37 Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42 (03) 590-3.
• 38 Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke J Cereb Circ 1998; 29 (01) 104-11.
• 39 Niehaus L, Böckeler GC, Kupsch A, Meyer BU. Normal cerebral hemodynamic response to orthostasis in Parkinson’s disease. Parkinsonism Relat Disord 2002; 08 (04) 255-9.
• 40 Onrot J, Goldberg MR, Hollister AS, Biaggioni I, Robertson RM, Robertson D. Management of chronic orthostatic hypotension. Am J Med 1986; 80 (03) 454-64.
• 41 Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllylä VV. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2009; 24 (05) 745-51.
• 42 Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Park Dis 2013; 2013: 906274.
• 43 Lyons KE, Pahwa R. The impact and management of nonmotor symptoms of Parkinson’s disease. Am J Manag Care 2011; 17 Suppl (Suppl. 12) S308-14.
• 44 Sánchez-Ferro A, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson’s disease. Front Neurol 2013; 04: 64.
• 45 Thomaides T, Bleasdale-Barr K, Chaudhuri KR, Pavitt D, Marsden CD, Mathias CJ. Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson’s disease, multiple system atrophy, and pure autonomic failure. Neurology 1993; 43 (05) 900-4.
• 46 Van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res Off J Clin Auton Res Soc 2000; 10 (01) 35-42.
• 47 Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs 2010; 24 (11) 941-68.
• 48 Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992; 232 (02) 139-45.
• 49 Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2007; 22 (11) 1543-9.
• 50 Smit AAJ. et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res Off J Clin Auton Res Soc 2004; 14 (03) 167-75.
• 51 Ten Harkel AD, van Lieshout JJ, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci Lond Engl 1994; 87 (05) 553-8.
• 52 Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc 1996; 71 (09) 847-53.
• 53 Bird ST, Delaney JAC, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40–85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013; 347: f6320.
• 54 Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005; 30 (02) 173-8.
• 55 Perez-Lloret S. et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18 (05) 501-5.
• 56 Hajjar I. Postural blood pressure changes and orthostatic hypotension in elderly patient: impact of antihypertension medication. Drugs Aging 2005; 22 (01) 55-68.
• 57 Vara LAGonzález, Muñoz PCacho. [Orthostatic hypotension and arterial hypertension. Are all calcium antagonists equal?]. Med Clínica 2000; 115 (13) 516.
• 58 Milazzo V, Stefano CD, Servo S, Crudo V, Fulcheri C. Drugs and orthostatic hypotension: evidence from literature. J Hypertens 2012; 01: 104.
• 59 Pursiainen V, Korpelainen TJ, Haapaniemi HT, Sotaniemi AK, Myllylä VV. Selegiline and blood pressure in patients with Parkinson’s disease. Acta Neurol Scand 2007; 115 (02) 104-8.
• 60 Haapaniemi TH. et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol 2000; 247 (11) 868-74.
• 61 Stryjer R, Klein C, Treves TA, Rabey JM. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson’s disease patients. Acta Neurol Scand 2005; 111 (02) 89-94.
• 62 Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology 1996; 47 (6 Suppl 3): S137-45.
• 63 Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol 2000; 57 (10) 1461-3.
• 64 Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf 2010; 33 (02) 147-61.
• 65 Mosnaim AD, Abiola R, Wolf ME, Perlmuter LC. Etiology and risk factors for developing orthostatic hypotension. Am J Ther 2010; 17 (01) 86-91.
• 66 Bouhaddi M. et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci Basic Clin 2004; 116 (1–2): 30-8.
• 67 Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson’s disease. Eur J Clin Pharmacol 1993; 45 (05) 419-23.
• 68 Brunton L. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill; 2011
• 69 Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979; 01 (8123): 954-6.
• 70 McDonald. Domperidone for drug-induced orthostatic hypotension. Jefferson Journal of Psychiatry 1992; 1081):. 12-16.
• 71 Singer W. et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63 (04) 513-8.
• 72 Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277 (13) 1046-51.
• 73 Haustein K. Antihypnotika. In: Schwabe U, Paffrath D. Arzneiverordnungs-Report 1998. Stuttgart: Gustav Fischer; 1998
• 74 Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res Off J Clin Auton Res Soc 2008; 18 Suppl (Suppl. 01) 19-24.
• 75 Hauser RA, Hewitt LA, Isaacson S. a (NOH306A). J Park Dis 2014; 04 (01) 57-65.
• 76 Maule S, Papotti G, Naso D, Magnino C, Testa E, Veglio F. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 2007; 07 (01) 63-70.
• 77 Schmidt C. et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord Off J Mov Disord Soc 2009; 24 (14) 2136-42.
• 78 Berganzo K. et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related?. J Neurol 2013; 260 (07) 1752-6.
• 79 Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40 (12) 1217-20.
• 80 Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to headup tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens 1998; 16 (10) 1433-41.
• 81 Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease – from mice and man. Pharmacol Ther 2006; 111 (03) 629-51.
• 82 Jordan J. Circulation. 2000; 101 (05) 504-9.